Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
223.96(c) 226.15(c) 226.14(c) 226.58(c) 234.06(c) Last
1 844 602 1 459 038 1 225 022 1 750 471 2 178 366 Volume
+0.95% +0.98% -0.00% +0.19% +3.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7 501 M - -
Net income 2021 2 296 M - -
Net cash position 2021 8 318 M - -
P/E ratio 2021 26,6x
Yield 2021 -
Sales 2022 8 231 M - -
Net income 2022 3 007 M - -
Net cash position 2022 12 053 M - -
P/E ratio 2022 20,3x
Yield 2022 -
Capitalization 59 510 M 59 510 M -
EV / Sales 2021 6,82x
EV / Sales 2022 5,77x
Nbr of Employees 3 400
Free-Float -
More Financials
Company
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.9%); - royalties and income from partnership, research, and development agreements (0.1%). Net sales break down geographically... 
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
01/12Vertex Pharmaceuticals - European Commission Approves KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
01/11Vertex's Cystic Fibrosis Combo Gets Extended EU Nod For Treating Children
MT
01/11Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment f..
MT
01/11European Commission Approves KAFTRIO« (ivacaftor/tezacaftor/elexacaftor) in Combination..
BU
01/11Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO« (iv..
CI
01/06RBC Raises Price Target on Vertex Pharmaceuticals to $268 From $265, Maintains Outperfo..
MT
01/04Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
BU
2021Diversified Healthcare Trust's Sale of 35% Stake in Boston Properties Lifts Liquidity A..
MT
2021Diversified Healthcare Trust to Sell 35% Stake in Joint Venture for $378 Million
MT
2021Wells Fargo Reinstates Vertex Pharmaceuticals With Overweight Rating, $270 Price Target
MT
2021PUMP / DUMP #13 : This week's gainers and losers
2021RBC Lifts Price Target on Vertex Pharmaceuticals to $265 From $250, Citing 'Strong' Pro..
MT
2021Equities Led Higher Midday by Energy, Financials Following BioNTech CEO Comment on Vacc..
MT
2021MIDDAY REPORT : US Stocks Led Higher by Energy, Financials Following BionTech CEO Comment ..
MT
2021Vertex Pharmaceuticals Up Over 7%, Best Performer in The S&P 500 and Nasdaq 100 So Far ..
DJ
More news
News in other languages on VERTEX PHARMACEUTICALS
01/11Vertex obtient l'approbation de la Commission européenne pour Kaftrio et l'Ivacaftor co..
01/11Vertex Pharmaceuticals Incorporated annonce que la Commission européenne approuve KAFTR..
2021Selon B. Riley, la vente par Diversified Healthcare Trust de 35 % de sa participation d..
2021NOVARTIS-CHEF : Möglicher Verkauf von Sandoz stösst auf Interesse
2021PUMP / DUMP #40 : Les Tops & Flops de la semaine
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 234,06 $
Average target price 263,74 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS6.58%59 510
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS, INC.-2.58%64 327
WUXI APPTEC CO., LTD.-3.88%52 722
BIONTECH SE-23.97%47 338
BEIGENE, LTD.-11.92%24 519